A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis

Summary

The purpose of this study is to determine the efficacy and safety of the study drug ixekizumab in Chinese participants with moderate-to-severe plaque psoriasis.

Timeline

Start

2018-04-26

Primary completion

2020-06-04

Completion

2020-06-04

Publications

• Gao X, Pan W, Zheng M, Li F, Dong X, Lv D, Guo Z, Li J, Wang X, Geng S. Efficacy and Safety Analysis in Chinese Patients with Moderate-to-Severe Psoriasis from a Phase 3 Trial: Impact of Treatment Withdrawal and Retreatment of Ixekizumab. Adv Ther. 2025 Jan;42(1):334-347. doi: 10.1007/s12325-024-03030-5. Epub 2024 Nov 13.
• Li X, Ding Y, Zhang C, Lu Y, Li F, Pan W, Guo S, Li J, Zhao B, Zheng J. Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Psoriasis and Special Body Area Involvement: Sub-analysis of a Randomized, Double-Blind, Multicenter Phase 3 Study. Adv Ther. 2025 Jan;42(1):146-163. doi: 10.1007/s12325-024-02976-w. Epub 2024 Sep 30.

Drugs

Indications